Real-world use of multigene signatures in early breast cancer: differences to clinical trials
ConclusionsIn this real-world series, Oncotype DX was the test almost exclusively used. Despite reimbursement being linked to pre-test chemotherapy recommendation, almost 3/4 patients resulted in the low-RS group. The significant proportion of node-positive patients ≤ 50 years tested indicates that oncologists considered Oncotype DX informative also in this population. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 1, 2024 Category: Cancer & Oncology Source Type: research
Effects of physical exercise during adjuvant chemotherapy for breast cancer on long-term tested and perceived cognition: results of a pragmatic follow-up study
ConclusionIn this pragmatic follow-up study, exercising and being overall more physically active during or after adjuvant chemotherapy for breast cancer was not associated with better tested or self-reported cognitive functioning, on average, 8.5 years after treatment. Future prospective studies are needed to document the complex relationship between exercise and CRCI in cancer survivors. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 1, 2024 Category: Cancer & Oncology Source Type: research
Deep learning-guided adjuvant chemotherapy selection for elderly patients with breast cancer
ConclusionOur results emphasize the potential of DL models in guiding adjuvant chemotherapy decisions for elderly breast cancer patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 1, 2024 Category: Cancer & Oncology Source Type: research
Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
ConclusionThis review found that one out of three patients becomes eligible for BCS after treatment with NET. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 1, 2024 Category: Cancer & Oncology Source Type: research
Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes
ConclusionApproximately one-third of patients with ≥ 3 positive SLNs do not undergo ALND; omission of ALND increased from 2018 to 2020. Studies assessing oncologic outcomes of patients with ≥ 3 positive SLNs who do and do not receive ALND are required. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 1, 2024 Category: Cancer & Oncology Source Type: research
High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy
ConclusionOur real-world data demonstrates high TIL is significantly associated with pCR rate in the K522 regimen and may potentially serve as a biomarker to select optimal treatment. The pCR rate of 48.4% in our study is lower than that reported in K522, potentially due to the smaller size of our study; however, this may also indicate differences between real-world data and clinical trial results. Larger studies are warranted to further investigate the role of immune cells in TNBC response to K522 and other treatment regimens. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 1, 2024 Category: Cancer & Oncology Source Type: research
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
Most men with newly appreciated metastatic prostate cancer are optimally treated with a backbone consisting of androgen receptor–directed therapy with or without taxane chemotherapy. Despite improvements in disease outcomes, prostate cancer remains an extremely heterogeneous disease with variable mechanisms of therapeutic resistance. As a result, it remains a leading cause of cancer-related death in men. Radiopharmaceutical therapy has emerged as an alternative, non–androgen receptor–directed treatment modality for metastatic castration-resistant prostate cancer that impacts patient survival and represent...
Source: Journal of Nuclear Medicine - May 1, 2024 Category: Nuclear Medicine Authors: Viscuse, P., Devitt, M., Dreicer, R. Tags: Continuing Education Source Type: research
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Conclusion: In the PHERGain trial, an increased SUVmax cutoff (≥77%) after 2 cycles of exclusive HP (with or without endocrine therapy) achieves a pCR in the range of the control arm with chemotherapy plus HP (59.5% vs. 57.7%, respectively), further identifying a subgroup of patients with HER2-addicted tumors. However, the original cutoff (≥40%) maximizes the number of patients who could avoid chemotherapy. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - May 1, 2024 Category: Nuclear Medicine Authors: Gebhart, G., Keyaerts, M., Guiot, T., Flamen, P., Ruiz-Borrego, M., Stradella, A., Bermejo, B., Escriva-de-Romani, S., Calvo Martinez, L., Ribelles, N., Fernandez-Abad, M., Albacar, C., Colleoni, M., Garrigos, L., Atienza de Frutos, M., Dalenc, F., Prat, Tags: Clinical Investigations Source Type: research
Cancers, Vol. 16, Pages 1759: Kinetics of IFN & gamma;-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors
In conclusion, our study elucidates the dynamic changes in cytokine profiles associated with serious irAE development during treatment with PD-(L)1 inhibitors. The study’s findings offer valuable insights into the intricate IFN-induced immune responses associated with irAEs and propose potential predictive markers for their severity. (Source: Cancers)
Source: Cancers - May 1, 2024 Category: Cancer & Oncology Authors: Leticia Alserawan Maria Mulet Ge òrgia Anguera Mariona Riudavets Carlos Zamora Rub én Osuna-Gómez Jorgina Serra-L ópez Andr és Barba Joaquín Ivana Sullivan Margarita Majem Silvia Vidal Tags: Article Source Type: research
Pembrolizumab response in stage IV luminal-type breast cancer with high microsatellite instability: a case report
ConclusionWe report a case of luminal-type breast cancer with bone metastases and MSI-High, which was treated with PEM and showed a rapid therapeutic response. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - May 1, 2024 Category: General Medicine Source Type: research
Tomotherapy in synchronous and metachronous bilateral breast cancer: Clinical experience
CONCLUSION: Our results show the efficacy of using helical Tomotherapy considering positive outcomes, being that three out of four patients are in remission with low acute toxicity and late complications. There are a small number of articles describing bilateral breast cancer treatment with helical Tomotherapy. On this occasion, our data could contribute to the studies of tolerant doses for organs at risk and improve the parameters of treatment plans for bilateral breast cancer. Since the small sample of patients with bilateral breast cancer limits the study, a larger cohort of patients is essential to obtain statistically...
Source: Clinical Breast Cancer - April 30, 2024 Category: Cancer & Oncology Authors: Yernar Orda Tanzhas Shayakhmetov Saniya Baiturova Daulet Berikbol Rauan Otynshiyev Aigul Brimova Bolat Saktashev Ainur Baisalbayeva Ainur Samigatova Source Type: research
Tomotherapy in synchronous and metachronous bilateral breast cancer: Clinical experience
CONCLUSION: Our results show the efficacy of using helical Tomotherapy considering positive outcomes, being that three out of four patients are in remission with low acute toxicity and late complications. There are a small number of articles describing bilateral breast cancer treatment with helical Tomotherapy. On this occasion, our data could contribute to the studies of tolerant doses for organs at risk and improve the parameters of treatment plans for bilateral breast cancer. Since the small sample of patients with bilateral breast cancer limits the study, a larger cohort of patients is essential to obtain statistically...
Source: Clinical Genitourinary Cancer - April 30, 2024 Category: Cancer & Oncology Authors: Yernar Orda Tanzhas Shayakhmetov Saniya Baiturova Daulet Berikbol Rauan Otynshiyev Aigul Brimova Bolat Saktashev Ainur Baisalbayeva Ainur Samigatova Source Type: research
ASO Author Reflections: Application of Robotic Technique for Treatment of Biliary Sclerosis from Hepatic Artery Infusion Pump Chemotherapy
Ann Surg Oncol. 2024 Apr 30. doi: 10.1245/s10434-024-15368-9. Online ahead of print.NO ABSTRACTPMID:38689170 | DOI:10.1245/s10434-024-15368-9 (Source: Ann Oncol)
Source: Ann Oncol - April 30, 2024 Category: Cancer & Oncology Authors: Maria Christodoulou Tara M Pattilachan Sharona Ross Emanuel Shapera Iswanto Sucandy Source Type: research
ASO Visual Abstract: Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis
Ann Surg Oncol. 2024 Apr 30. doi: 10.1245/s10434-024-15339-0. Online ahead of print.NO ABSTRACTPMID:38689171 | DOI:10.1245/s10434-024-15339-0 (Source: Ann Oncol)
Source: Ann Oncol - April 30, 2024 Category: Cancer & Oncology Authors: Kavin Sugumar Henry Stitzel Victoria Wu David Bajor Sakti Chakrabarti Madison Conces Lauren Henke Melissa Lumish Amit Mahipal Amr Mohamed Jordan M Winter Jeffrey M Hardacre John B Ammori Jennifer E Selfridge Lee M Ocuin Source Type: research
Successful treatment with nivolumab in a patient with gastric cancer with severe liver failure resulting from multiple liver metastases: A case report
Oncol Lett. 2024 Apr 18;27(6):271. doi: 10.3892/ol.2024.14404. eCollection 2024 Jun.ABSTRACTGastric cancer (GC) is a globally prevalent and deadly malignancy often diagnosed at advanced stages, which can be accompanied by liver metastases. Conventional chemotherapy is contraindicated in patients with severe liver failure because several chemotherapeutic agents are metabolized by the liver. The present study reports on the successful use of nivolumab in a patient with advanced GC and severe liver failure owing to multiple liver metastases. A 57-year-old man was admitted to Shimane Prefectural Central Hospital (Izumo, Japan)...
Source: Oncology Letters - April 30, 2024 Category: Cancer & Oncology Authors: Fumiyoshi Ikejiri Kanako Yokomizo Kenji Tamura Source Type: research
